与TNF抑制剂相比托法替布相对风险不同的两个亚人群的识别:开放标签随机对照研究ORAL Surveillance分析
基于ORAL Surveillance研究的事后分析,按年龄和吸烟状态将患者分为两个亚人群:年龄≥65岁或曾吸烟者(高风险)使用托法替布(合并剂量)相比TNF抑制剂,恶性肿瘤(除外非黑色素瘤皮肤癌)、主要不良心血管事件、心肌梗死、静脉血栓栓塞和全因死亡的风险增加(HR 1.41-5.19);年龄<65岁且从不吸烟者(低风险)风险无明显增加(HR≈1.0),绝对风险低,并在托法替布类风湿关节炎、银屑病关节炎和溃疡性结肠炎项目中得到印证。
要点
- 年龄≥65岁或曾吸烟的类风湿关节炎患者使用托法替布相比TNF抑制剂,多种安全性结局风险增加(HR 1.41-5.19)。
- 年龄<65岁且从不吸烟者使用托法替布相比TNF抑制剂风险无明显增加(HR≈1.0),绝对风险低。
- 上述风险差异因素可指导托法替布的个体化获益/风险评估和临床决策。
核心结论
- ORAL Surveillance事后分析识别出与TNF抑制剂相比相对风险不同的两个托法替布亚人群。
- 高风险仅限于年龄≥65岁或吸烟定义的患者,这些区分性风险因素解释了托法替布相比TNF抑制剂观察到的超额风险。
- 这些发现可指导托法替布的个体化获益/风险评估和临床决策。
研究设计与样本
- 基于ORAL Surveillance(一项事件驱动、纳入风险富集患者的开放标签随机对照研究)的事后分析。
- 患者为年龄≥50岁、伴有≥1项额外心血管风险因素的类风湿关节炎患者,接受托法替布5 mg或10 mg每日两次或TNF抑制剂治疗。
- 按年龄和吸烟状态单独及联合评估风险比(HR)和发生率,并在托法替布开发项目中验证结果。
主要发现
- 年龄≥65岁或曾吸烟定义的高风险组,托法替布(合并剂量)相比TNF抑制剂,恶性肿瘤(除外非黑色素瘤皮肤癌)、主要不良心血管事件、心肌梗死、静脉血栓栓塞和全因死亡的HR为1.41-5.19。
- 年龄<65岁且从不吸烟的低风险组,随访至6年,托法替布相比TNF抑制剂风险无明显增加(HR≈1.0),绝对风险保持低水平。
- 低风险组结果在托法替布类风湿关节炎、银屑病关节炎和溃疡性结肠炎项目中得到印证,观察期长达10年。
关键数值与推荐
- 高风险定义:年龄≥65岁或曾吸烟;低风险定义:年龄<65岁且从不吸烟。
- 高风险组托法替布(合并剂量)相比TNF抑制剂的HR范围为1.41-5.19(针对恶性肿瘤(除外非黑色素瘤皮肤癌)、主要不良心血管事件、心肌梗死、静脉血栓栓塞和全因死亡)。
- 低风险组托法替布相比TNF抑制剂的HR≈1.0,随访至6年。
临床怎么用
- 原文结论指出这些发现可指导托法替布的个体化获益/风险评估和临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, 'high-risk' and 'low-risk') with tofacitinib versus tumour necrosis factor inhibitors (TNFi). METHODS: Patients with rheumatoid arthritis aged ≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times a day or TNFi. Prior analyses had identified age and smoking as risk factors of particular interest across safety outcomes. Hazard ratios (HRs) and incidence rates were evaluated by age and smoking individually and in combination. Results were validated across tofacitinib development programmes. RESULTS: 'Age ≥65 years or ever smoker' defined a group ('high-risk') with increased risk of malignancies (excluding non-melanoma skin cancer), major adverse cardiovascular events, myocardial infarction, venous thromboembolism and all-cause death with tofacitinib (combined doses) versus TNFi (HRs 1.41-5.19). In patients 'aged <65 years and never smokers' ('low-risk'), there was no detectable risk increase with tofacitinib versus TNFi (HRs ≈1.0) up to 6 years of follow-up, and absolute risk remained low and was corroborated across tofacitinib rheumatoid arthritis, psoriatic arthritis and ulcerative colitis programmes with up to 10 years of observation. CONCLUSIONS: This posthoc analysis of ORAL Surveillance identified two tofacitinib subpopulations with different relative risk versus TNFi. High risk was confined to patients defined by distinct risk factors age ≥65 years or smoking, and these differentiating risk factors accounted for the excess risk observed with tofacitinib versus TNFi. These findings can guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib. TRIAL REGISTRATION NUMBERS: NCT02092467, NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02281552, NCT02187055, NCT02831855, NCT00413699, NCT00661661, NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612, NCT01877668, NCT01882439, NCT01976364.
引用
- Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023. PMID: 36931693. doi:10.1136/ard-2022-223715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。